Compound ID | 1218

Update compound information

Meropenem/Nacubactam (OP0595/ RG6080)

Class: Drug combination: beta-lactam (carbapenem) + beta-lactamase inhibitor (diazabicyclooctane)

Spectrum of activity: Gram-negative
Details of activity: Bacterial infections
Combined with other compounds: yes
Institute where first reported: Meiji Seika Pharma Co. Ltd./Fedora Pharmaceuticals Inc. (Roche licensee)
Highest developmental phase: Phase 1
Development status: Active
External links:
Guide to Pharmacology: nacubactam
Main Source: https://www.meiji.com/global/
Citations:
  • https://idsa.confex.com/idsa/2018/webprogram/Paper71491.html
  • https://www.ncbi.nlm.nih.gov/pubmed/30012751
  • https://www.ncbi.nlm.nih.gov/pubmed/30590470

    • AntibioticDB is supported by GARDP.

    If you have feedback, experience problems, or are interested in a collaboration, please contact us.

    Terms and conditions

    The content of this site is intended for educational and scientific research purposes only and not as a source of medical advice or consultation.